title: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.
abstract: While use of hormone-replacement therapy (HRT) effectively alleviates menopausal symptoms and prevents osteoporosis and possibly cardiovascular disease, there is concern of a detrimental impact on breast-cancer risk. There is a particular lack of data regarding the effect of long-term use of oestrogen-progestin combinations on breast-cancer risk. We conducted a large epidemiological study in Sweden, where combined oestrogen-progestin treatment has been predominant, to examine the influence of different regimens of menopausal hormone therapy on breast-cancer risk. In this population-based case-control study, 3,345 women aged 50 to 74 years with invasive breast cancer (84% of all eligible) and 3,454 controls of similar age (82% of all selected) were included. Mailed questionnaires and telephone interviews were used to collect detailed information on use of hormone replacement and on potential confounding factors. Odds ratios (OR) and 95% confidence intervals (CI) were estimated through multiple logistic regression. There was a trend of increasing breast-cancer risk with duration of oestrogen/oestrogen-progestin use (OR for women treated at least 10 years, 2.43; 95% CI, 1.79-3.30, as compared to never-users), with statistically significant estimates only for women with BMI<27 kg/m2. Excess risks were observed to current use and use that ceased more than 10 years ago (OR for women treated at least 5 years, OR was 2.68, 95% CI, 2.09-3.42, and OR 2.57, 95% CI, 1.28-5.15, as compared with never-users, respectively). A positive association which was noted for use of oestrogen combined with testosterone-derived progestins appeared especially pronounced with continuously combined regimens. Long-term use of replacement oestrogens with or without progestins may substantially increase the incidence of post-menopausal breast cancer, particularly among non-obese women.
authors: Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden. Cecilia.Magnusson@mep.ki.se
authors: C
authors: C
authors: Magnusson
authors: J A
authors: JA
authors: Baron
authors: N
authors: N
authors: Correia
authors: R
authors: R
authors: Bergström
authors: H O
authors: HO
authors: Adami
authors: I
authors: I
authors: Persson
mesh_terms: D001943:Breast Neoplasms / Q000209:etiology*; D004967:Estrogens / Q000009:adverse effects*; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D011372:Progestins / Q000009:adverse effects*; D012306:Risk
chemical_list: D004967:Estrogens; D011372:Progestins